(MENAFN) Pfizer and BioNTech SE stated Wednesday that they had reached a USD3.2 billion contract with the U.S. administration for 105 million shots of their COVID-19 inoculation.
The agreement comprises new versions of the doses, and they would be sent by the fall, awaiting a decision by the Food and Drug Administration (FDA).
Federal officials state the agreement includes the option to purchase a total of 300 million inoculation shots.
This comes as Pfizer announced Thursday that it is looking for full authorization for its oral COVID antiviral treatment Paxlovid by the FDA.
The drug would be used for the cure of COVID-19 in inoculated and unvaccinated people at high danger for development to severe disease.
Paxlovid is now authorized for emergency use for the cure of mild-to-moderate COVID-19 in adults and kids aged 12 years and older, weighing more than 88 lbs, with positive results of direct SARS-CoV-2 viral testing, and who are at high danger for progression to severe COVID-19.
MENAFN04072022000045012476ID1104474773
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.